Perrigo Q1 revenue falls 7%, misses estimates amid weak demand

Overview

• Ireland-based consumer self-care firm's Q1 revenue declined and missed analyst expectations

• Adjusted EPS for Q1 beat analyst expectations

• Company completed Dermacosmetics business sale post-quarter to support debt reduction

Outlook

• Perrigo maintains full-year 2026 outlook, expecting second-half improvement

• Company sees 2026 core net sales growth of (3.5)% to +0.5%

• Perrigo expects 2026 core adjusted EPS of $2.25 to $2.55

Result Drivers

• LOWER CONSUMER DEMAND - Co said lower consumption in the U.S. and Europe, including reduced seasonal incidence of cough and cold, weighed on net sales

• MARKET SHARE GAINS - Market share gains, supported by innovation launches and Women's Health products, partially offset sales declines

• GROSS MARGIN PRESSURE - Lower net sales volumes and prior-year manufacturing volume headwinds reduced gross margin, partly offset by tariff recoveries and favorable currency

Company press release: ID:nPn3DK5y3a

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Perrigo Company PLC is $16.50, about 41.8% above its May 5 closing price of $11.64

• The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.